



1

2

3

4

5

6

7

8

9

10

11

12

32

33

44

# Original Article

# Influence of immunosuppressive regimen on diffusivity and oxygenation of kidney transplants - analysis of functional MRI data from the randomized ZEUS trial

Laila-Yasmin Mani<sup>1\*</sup>, Jasna Cotting<sup>2</sup>, Bruno Vogt<sup>1</sup>, Ute Eisenberger<sup>3,4</sup> and Peter Vermathen<sup>2</sup>

- <sup>1</sup> Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Departments of Biomedical Research and Radiology, University of Bern, Bern, Switzerland
- University Hospital Essen, Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
  - Nephrological Centre Lower Saxony; Hospital Hann. Münden; Hann. Münden, Germany
- Correspondence: Laila.Mani@insel.ch; Tel.: 00 41 31 632 31 90

Abstract: The ZEUS study was a multi-center randomized controlled trial investigating the effect of 13 an early conversion from ciclosporin-based to an everolimus-based regimen on graft function 14 twelve months post-transplantation. In this investigator-initiated sub-study, functional magnetic 15 resonance imaging (fMRI) of kidney grafts was prospectively performed to non-invasively assess 16 differences in graft oxygenation, diffusion and perfusion between groups and time-points using 17 diffusion-weighted imaging (DWI) and blood oxygen level-dependent (BOLD)-MRI. Sixteen pa-18 tients underwent DWI and BOLD-MRI at months 4.5 and 12 post-transplantation on a 3 Tesla and 19 1.5 Tesla (n=3) MR scanner. After exclusion due to image quality, outlier values or missing data, 20 DWI was analyzed in ten, BOLD in eight subjects. The diffusion coefficient ADCD decreased in the 21 CsA-group over time, whereas it increased in the EVE-group (p=0.046, medulla). The change in 22 ADC<sub>D</sub> from month 4.5 to 12 significantly differed between groups in cortex (p=0.033) and medulla 23 (p=0.019). In BOLD, cortico-medullary transverse relaxation rate R2\* increased (decreased tissue ox-24 ygen) in the CsA-treated and decreased in the EVE-treated group over time. Similarly, R2\* values 25 at month 12 were higher in the CsA- vs. EVE-treated group. There was no significant difference for 26 the perfusion fraction F<sub>P</sub>. In conclusion, this prospective sub-study of the ZEUS trial suggests an 27 impact of immunosuppressive regimen on fMRI parameters of the kidney graft. 28

Keywords: kidney transplantation; functional MRI; diffusion-weighted imaging (DWI); blood oxy-29 gen level-dependent (BOLD); intravoxel incoherent motion imaging (IVIM); ZEUS study; Cyclo-30 sporin; Everolimus; calcineurin inhibitors; mTOR inhibitors 31

1. Introduction

Kidney transplantation is the treatment of choice for patients with end-stage kidney 34 disease prolonging survival [1]. Thanks to highly efficient immunosuppressive therapies, 35 a dramatic reduction in the risk of allograft rejection has been achieved since its early 36 period. Until now, the mainstay of post-transplant immunosuppressive regimens are cal-37 cineurin inhibitors acting on T cell and T cell-dependent B cell activation. However, major 38 adverse effects including nephrotoxicity, arterial hypertension and de novo diabetes 39 mellitus limit their usefulness in kidney transplant recipients [2]. Hence, existing efforts 40 target therapeutic strategies maximally limiting the exposition to calcineurin inhibitors 41 either by dose reduction, by shortening of administration period or by replacement by 42 Attribution NQTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 43

Citation: Lastname, F.; Lastname, F.; Lastname, F. Title. J. Clin. Med. 2022, 11, x. https://doi.org/10.3390/xxxxx

Academic Editor: Firstname Lastname

Received: date Accepted: date Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons (https://creativecommons.org/license s/by/4.0/).

2 of 15

53

54

55

56

57

58

59

60

61 62

The ZEUS study was a multi-center open-label randomized controlled trial designed to 45 investigate the effect of an early conversion from a calcineurin inhibitor-based immuno-46 suppression with ciclosporin (CsA) to a mammalian-target-of-rapamycin inhibitor-based 47 regimen with everolimus (EVE) on graft function twelve months post-transplantation [6]. 48An improvement of the estimated glomerular filtration rate (eGFR) at twelve months was 49 demonstrated in the EVE-treated as compared to the CsA-treated group, which persisted 50 five years post-transplant, despite a non-significantly higher number of rejection episodes 51 [6, 7]. 52

Functional magnetic resonance imaging (fMRI) techniques represent an attractive diagnostic tool for renal investigations allowing the non-invasive simultaneous assessment of several aspects of kidney function such as tissue structure, perfusion and oxygenation in addition to morphological imaging, without need for contrast media [8, 9]. Diffusion-weighted imaging (DWI) evaluates organ diffusivity and microperfusion, while blood oxygen level dependent (BOLD)-MRI assesses tissue oxygenation. Whereas DWI has been investigated as a non-invasive marker of kidney function, BOLD has proven particularly useful to study acute and chronic effects of various interventions [9-12].

The purpose of this investigator-initiated local sub-study of the ZEUS trial was the evalu-63 ation of additional aspects of kidney graft function according to the immunosuppressive 64 regimen using fMRI methods. With the exception of one study performing BOLD after 65 acute intake of ciclosporin, this question had not been addressed so far to the best of our 66 knowledge [13]. Due to the known acute and chronic effects of calcineurin inhibitor ne-67 phrotoxicity including vasoconstriction of afferent arterioles and development of intersti-68 tial fibrosis and tubular atrophy (IFTA), we hypothesized that diffusivity and microperfu-69 sion as measured by DWI as well as tissue oxygenation measured by BOLD-MRI of kidney 70 grafts differ between patients treated with ciclosporin as opposed to everolimus [14]. The 71 results show an improvement of graft diffusivity and a tendency for ameliorated tissue 72 oxygenation after switch to everolimus as compared to patients maintained on ciclo-73 sporin. 74

### 2. Materials and Methods

The protocol of the present investigator-initiated prospective single-center sub-study 76 of the ZEUS trial was approved by the local ethics committee (Canton of Bern, Switzerland, approval number 2004/213) and conducted in accordance with the Declarations of 78 Helsinki and Istanbul [15, 16]. 79

### 2.1. Study population

All kidney transplant recipients included in the ZEUS trial from our study center 81 were eligible for the current study [6]. Specific exclusion criteria were lack of consent to 82 participate in the sub-study, body weight >200 kg, classical contraindications to MRI as 83 well as implanted metallic material without prior 3T-MRI after implantation. Among the 84 300 study participants of the ZEUS study, 37 patients had been enrolled from our center 85 and represented the screening population for this sub-study. 86

### 2.2. Study design

The ZEUS study was a 12-month multi-center randomized controlled parallel-group 88 trial, the protocol of which has been published previously [6]. Patients were screened 89 among participants of the ZEUS trial before randomization at the outpatient University 90 Clinic for Nephrology and Hypertension in Bern (Figure 1). Written informed consent 91 was obtained from each participant prior to inclusion. The two study visits took place at 92 baseline (4.5 months after transplantation, before randomization within the ZEUS trial) as 93 well as at month 12 after transplantation. A light meal was allowed on the study day. 94

87

75

Laboratory tests including serum creatinine, serum urea, CsA trough levels and urinary 95 protein as well as ambulatory blood pressure measurement (ABPM), duplex ultrasound 96 scan and functional MRI of the kidney graft were performed at both visits. Baseline clini-97 cal characteristics based on medical chart review and EVE trough level were determined 98 at baseline- and 12 month-visits respectively. In addition, protocol transplant biopsies 99 were performed at baseline and 12 months as part of this study amendment. 100

101

3 of 15



Figure 1. Study design. DWI (diffusion-weighted imaging); BOLD (blood oxygen level dependent-MRI); ABPM (ambulatory blood pressure measurement); DUS (duplex ultrasound scan). 104

### 2.3. MRI protocol

MRI data were acquired on a 3.0 T whole body MR Scanner (Tim Trio®; Siemens 106 Healthcare, Erlangen, Germany) for all subjects but three who underwent MRI on a 1.5 T 107 MR scanner (Sonata®; Siemens Healthcare, Erlangen, Germany). During each of the two 108 MRI sessions anatomical MRI, DWI and BOLD-MRI were performed. 109

Intravoxel incoherent motion (IVIM)-DWI yielded the perfusion-cleared apparent diffu-111 sion coefficient ADC<sub>D</sub> and the perfusion fraction F<sub>P</sub>. Coronal multisection echoplanar DWI 112 was performed with the following parameters: 11 slices (thickness: 5mm, intersection gap: 113 1mm), field of view (FOV)=400x400mm2, matrix=128x128, six averages, band-114 width=2300Hz/pixel and partial Fourier 6/8. Ten diffusion gradient b-values were applied 115 (in sec/mm2): b=0, 10, 20, 50, 100, 180, 300, 420, 550, and 700. The gradients were applied 116 in three orthogonal directions and subsequently averaged, minimizing effects of diffusion 117 anisotropy. Parallel imaging (iPAT, mSENSE) with a reduction factor of 2 was applied. A TE of 64msec was used. Acquisition time for DWI was 8:06min. 119

BOLD-MRI takes advantage of deoxygenated hemoglobin as an endogenous contrast 121 agent, which influences the relaxation time T2\* yielding the transverse relaxation rate 122  $R2^*$  (equal to  $1/T2^*$ ) which correlates to tissue oxygen content provided that confounding 123 factors such as blood volume or hydration state are excluded [8, 9]. For BOLD-MRI, a 124

103

102

105

110

118

multiple gradient recalled echo sequence (mGre) was used. Four to six coronal slices were 125 acquired with a slice thickness of 5mm and an intersection gap of 1mm, a FOV of 126 400x400mm2, a matrix size of 256x256, on average. Other parameters were: TR of 65msec, 127 TE of 6–52msec, inter-echo spacing time of 4.2msec, flip angle of 30°, and bandwidth was 128 330Hz/pixel. Twelve T2\*-weighted images, corresponding to 12 different echoes, were ac-129 quired for each slice within a single breath-hold of 17 sec. 130

A maximum of three regions of interest (ROIs) traced in medulla and cortex were ana-132 lyzed in every slice (BOLD: 4-6, DWI: 4 slices) for each medulla and cortex. ROIs were 133 manually defined by the same blinded investigator on images handed over in a random 134 fashion. ROIs were traced in the medulla and cortex. Data were analyzed using in-house 135 custom-scripts written in IDL® and MATLAB®. The obtained values were read into MS 136 Excel® for further statistical processing. GraphPad Prism 9® was used for figure prepa-137 ration. 138

### 2.4. Duplex ultrasound scan

Duplex ultrasound scan was performed at both study visits by the same experienced 140 nephrologist on a Siemens Acuson Sequoia 512 machine. Recorded parameters were re-141 sistive indices (RI) measured at intralobar arteries (as a mean of superior, median and 142 lower). 143

# 2.5. Ambulatory blood pressure measurement

Ambulatory blood pressure measurement was performed at both study visits using 145 a Profilomat II® device (Disetronic Medical Systems, Burgdorf, Switzerland). Recorded 146 variables were the overall mean arterial systolic, diastolic and mean pressures and dip-147 ping effect (in mmHg). 148

# 2.6. Laboratory analyses

Laboratory analyses were performed according to the ZEUS study protocol as spec-150 ified in section 2.2 in the central laboratory of the Bern University Hospital. Glomerular 151 filtration rate was estimated (eGFR) according to chronic kidney disease epidemiology 152 2021 formula. 153

### 2.7. Histopathological analysis of kidney grafts

Histopathological analysis of renal tissue obtained from protocol graft biopsies was 155 performed according to clinical routine in the department of pathology of the University 156 of Bern. Biopsy reports were retrospectively assessed for the presence of IFTA, arteriolar 157 hyalinosis and rejection in a semi-quantitative manner. 158

#### 2.8. Outcome measures

Primary outcome were the difference between the CsA-treated vs EVE-treated pa-160 tient groups in ADC<sub>D</sub>, F<sub>P</sub>, R2\* and cortico-medullary ratios (MCR) MCR ADC<sub>D</sub>, MCR F<sub>P</sub> 161 and MCR R2\* at month 12 as well as in the change of ADCD, FP and R2\* and the MCR from 162 month 4.5 to month 12. Secondary outcomes were the change in ADC<sub>D</sub>, F<sub>P</sub>, R2\* and cortico-163 medullary ratios from month 4.5 to month 12 in each medication group; the difference in 164 mean RI and overall mean systolic, diastolic and mean blood pressure and dipping values 165 between time-points for medication groups and the difference in changes from baseline 166 to month 12 between groups; the correlation of fMRI parameters and their changes over 167 time across and within medication groups with eGFR, RI, overall mean systolic, diastolic 168 and mean blood pressure as well as dipping values. 169

170

4 of 15

139

144

149

154

159

5 of 15

180

181

182

189

Continuous variables were expressed as means with standard deviation (SD) or me-171 dians with range between minimal and maximal value. Wilcoxon-signed-rank-test was 172 used for cortico-medullary differences and longitudinal changes in fMRI, RI and ABPM 173 parameters within groups. Mann-Whitney-U-test was performed for comparisons across 174 groups of absolute fMRI, RI and ABPM values as well as of longitudinal changes in these 175 parameters. Correlations between fMRI absolute values, changes over time and differ-176 ences across groups with eGFR, medication levels, RI and ABPM were determined by 177 Kendall's Tau correlation coefficient analysis. Data were analyzed using IBM SPSS Statis-178 tics 24<sup>®</sup> and MS Office 2007<sup>®</sup>. 179

3. Results

#### 3.1. Study population

#### 3.1.1. Patient enrolment

From September 2005 until December 2006, 70 patients received a kidney transplant 183 in our center and were screened at the outpatient University Clinic for Nephrology and 184 Hypertension in Bern for participation in the ZEUS trial and the MRI substudy. A total of 185 37 subjects were enrolled in the ZEUS trial, 16 of which were included in the current study 186 and underwent MR measurements. One patient was subsequently excluded because of 187 lack of randomization (Figure 2). 188



190

193

Figure 2. Flow chart. Patient screening and data exclusion. DWI (diffusion-weighted imaging);191BOLD (blood oxygen level dependent-MRI).192

#### 3.1.2. Patient characteristics

Baseline clinical characteristics are shown in Table 1. All of the patients were of Caucasian origin and mostly first transplant recipients with relatively preserved transplant function. Seven and nine subjects were randomized to the CsA and EVE groups respectively. There were more female subjects in the CsA group whereas living donor type was more frequent in the EVE group. Other variables were homogenously distributed among medication groups.

#### J. Clin. Med. 2022, 11, x FOR PEER REVIEW

	CsA group (n=7)	EVE group (n=9)
Age at transplantation (years)	48±9 (52; 30-54)	47±12 (47; 29-62)
Female gender (%)	57	33
Living donor (%)	0	23
Transplant episode (%)		
- first	71	78
eGFR (ml/min/1.73 m2)	61±8 (65; 45-69)	66±27 (57; 35-109)
24 hour-blood pressure (mmHg)		
- systolic	121±10	121±14
- diastolic	77±8	80±13
- mean	100±9	101±13
Time to MR scan (months)		
- baseline MR	3.8±0.7	3.7±0.5
- second MR	11±0.5	11.9±0.6

Table 1. Baseline characteristics of the subjects (n=16).

Values are expressed as mean ± standard deviation (median; range) or as percentage of patients, as201appropriate. n (number); CsA (ciclosporin); EVE (everolimus); eGFR (estimated glomerular filtra-202tion rate) estimated according to chronic kidney disease epidemiology collaboration formula; MR203(magnetic resonance).204

#### 3.2. Data quality

The MRI protocol including morphological sequences, DWI and BOLD could be per-206 formed in all of the patients at baseline and in 13 patients on study day 2. Subjects without 207 second measurement were not included in the analysis (Figure 2). Data of two patients 208 had to be excluded due to poor image quality resulting in analyzable data for 11 patients 209 in each MR modality. In DWI, one patient had to be excluded because of outlier values 210 (deviation >mean ± 2 SD); in BOLD, three patients were excluded due to field strength (1.5 211 T). A mean scanning time of one hour was met per session. DWI- and BOLD-derived mean 212 values and SD ranges were roughly in line with previously reported values (Table 2) [17-213 20]. Low SD values confirmed measurement stability. 214

**Table 2.** Overall mean values and standard deviations of diffusion-weighted imaging (DWI)- and215blood oxygen level dependent (BOLD)-MRI-derived parameters.216

	Medulla	Cortex
ADCD	$204.4 \pm 15.0$	$203.0 \pm 16.1$
$\mathbf{F}_{\mathbf{P}}$	$13.0 \pm 4.0$	$14.6 \pm 3.1$
R2*	$26.1 \pm 3.0$	$17.5 \pm 2.7$

ADCD (diffusion coefficient); FP (perfusion fraction); R2\* (transverse relaxation rate).

# 3.3. Diffusion-weighted imaging

#### 3.3.1. Diffusion coefficient ADCD

Mean overall medullary and cortical values for the apparent diffusion coefficient 220 ADC<sub>D</sub> as a marker of pure diffusion are shown in Table 2 and Table 3. No cortico-medul-221 lary difference of the ADC<sub>D</sub> was noted (p=0.65 at month 4.5, p=0.51 at month 12). In the 222 CsA-treated group, medullary and cortical ADC<sub>D</sub> values decreased in all but one subject 223 from month 4.5 to month 12 (p=0.14 and p=0.14), whereas in the EVE-treated group, me-224 dullary and cortical ADC<sub>D</sub> values increased from month 4.5 to month 12, reaching statis-225 tical significance for the medulla (p=0.046 and p=0.12, respectively). At baseline, there was 226 a tendency for higher ADC<sub>D</sub> values in the group randomized to CsA as compared to the 227 group randomized to EVE. In contrast, at month 12, ADCD values were higher by trend in 228 the EVE-treated group vs. the CsA-treated group (Table 3, Figure 3). This was the result 229 of a significant difference of the mean change in ADC<sub>D</sub> from month 4.5 to month 12 over 230 time, which was negative in the CsA-treated group and positive in the EVE-treated group 231

200

6 of 15

218

217

205

J. Clin. Med. 2022, 11, x FOR PEER REVIEW

(Table 3, Figure 4). There were no differences in MCR ADC<sub>D</sub> between time-points (p=0.47 232 for CsA-group; p=0.17 for EVE-group) or medication groups. 233

**Table 3.** DWI-derived pure diffusion coefficient according to medication group and time-point.
 234

	CsA (n=4)	EVE (n=6)	<i>p</i> -value <sup>1</sup>
Month 4.5			
ADC⊳ medulla	210.4±25.0	201.0±7.5	0.26
ADCD cortex	212.1±22.2	201.1±10.0	0.26
MCR ADCD	0.99±0.02	1.01±0.03	0.87
Month 12			
ADC⊳ medulla	195±14.5	210.0±12.2	0.17
ADCD cortex	193.5±20.0	206.3±13.7	0.26
MCR ADCD	1.01±0.05	1.02±0.04	0.78
Change month 4.5-12			
∆ADC⊳ medulla	-15.4±18	9.0±7.6	0.019
$\Delta ADC_D$ cortex	-18.6±23.8	6.2±7.3	0.038
$\Delta$ MCR ADCD	0.02±0.04	$0.01 \pm 0.03$	0.54

<sup>1</sup> Mann-Whitney U-test. Values are expressed as mean  $\pm$  standard deviation. CsA (ciclosporin); EVE (everolimus); ADC<sub>D</sub> (diffusion coefficient) in 10<sup>-5</sup>mm<sup>2</sup>/s. 236

237

238

239



**Figure 3. DWI-derived diffusion coefficient ADC**<sub>D</sub>. Diffusion coefficient ADC<sub>D</sub> according to medication group and time-point. CsA (ciclosporin); EVE (everolimus); ADC<sub>D</sub> (diffusion coefficient). 242







243

246

257

Figure 4. Change in DWI-derived diffusion coefficient. Change in diffusion coefficient ADCD from244month 4.5 to month 12. CsA (ciclosporin); EVE (everolimus); ADCD (diffusion coefficient).245

# 3.3.2. Perfusion fraction $F_P$

Mean medullary and cortical values for the fraction of perfusion FP are shown in Ta-247 ble 2 and Table 4. As with ADC<sub>D</sub>, no significant cortico-medullary differences were found 248 for  $F_P$  at both time-points (p=0.58 at month 4.5, p=0.059 at month 12). There was no differ-249 ence in F<sub>P</sub> or MCRF<sub>P</sub> between medication groups at baseline nor at twelve months. Fur-250 thermore, no difference in the change over time of F<sub>P</sub> or MCRF<sub>P</sub> according to medication 251 group was noted. Overall, no change was seen from baseline to month 12 across nor 252 within medication groups in  $F_P$  in medulla (p=0.17 for both groups; p=0.72 for the CsA-253 group; p=0.12 for the EVE-group), in cortex (p=0.29 for both groups; p=0.72 for the CsA-254 group; p=0.35 for the EVE-group) nor in MCRF<sub>P</sub> (p=0.45 for both groups; p=0.47 for the 255 CsA-group; *p*=0.25 for the EVE-group). 256

Table 4. DWI-derived perfusion fraction according to medication group and time-point.

	CsA (n=4)	EVE (n=6)	<i>p</i> -value <sup>1</sup>
Month 4.5			
F <sub>P</sub> medulla	12.8±1.5	15.4±5.9	0.26
F <sub>P</sub> cortex	15.3±3.8	15.4±4.4	1.00
MCR FP	0.9±0.3	1.0±0.2	0.87
Month 12			
F <sub>P</sub> medulla	13.4±3.5	10.6±2.1	0.17
F <sub>P</sub> cortex	14.4±1.5	13.4±1.9	0.48
MCR FP	0.9±0.3	0.8±0.1	0.28
Change month 4.5-12			
$\Delta F_P$ medulla	0.6±2.5	-4.8±7.1	0.17
$\Delta F_P$ cortex	-0.9±4.0	-2.0±4.4	0.76
$\Delta$ MCR F <sub>P</sub>	0.05±0.36	-0.2±0.3	0.34
	1		

<sup>1</sup> Mann-Whitney U-test. Values are expressed as mean  $\pm$  standard deviation. CsA (ciclosporin); EVE (everolimus); F<sub>P</sub> (perfusion fraction) in %.

259 260



261

264

Figure 5. DWI-derived perfusion fraction. Perfusion fraction FP according to medication group and262time-point. CsA (ciclosporin); EVE (everolimus); FP (perfusion fraction).263

#### 3.4. Blood oxygen level dependent-imaging

Mean medullary and cortical values for the transverse relaxation rate R2\* are shown 265 in Table 2 and Table 5. As expected, significant cortico-medullary differences were shown 266 at both time-points (p=0.012) with lower cortical R2\* values, compatible with the known 267 relative medullary hypoxia. Inverse trends were noted according to medication assign-268 ment including increasing medullary R2\* values (i.e. reduced tissue oxygenation) in all of 269 the CsA-treated vs. decreasing medullary and cortical R2\* values in five and four of six 270 EVE-treated patients respectively (Figure 6). However, the number and distribution of 271 cases across groups at month 12 precluded formal statistical analysis. No changes in me-272 dullo-cortical distribution were seen between medication groups or time-points. 273

Table 5. BOLD-derived transverse re	laxation rate accordin	g to medication	group and time-poir	ıt. 274
		0	0 · · F · · · · F ·	

	CsA (n=2)	EVE (n=6)	
Month 4.5			_
R2* medulla	24.7±2.7	27.4±3.7	
R2* cortex	17.0±3.2	18.6±3.1	
MCR R2*	1.5±0.1	1.5±0.1	
Month 12			_
R2* medulla	27.1±4.1	25.0±1.9	
R2* cortex	17.2±0.3	16.7±2.7	
MCR R2*	1.6±0.3	1.5±0.3	
Change month 4.5-12			
$\Delta R2^*$ medulla	2.4±1.4	-2.4±3.5	
$\Delta R2^*$ cortex	0.2±3.5	-1.9±3.3	
$\Delta$ MCR R2*	0.1±0.4	0.1±0.3	

Values are expressed as mean ± standard deviation. CsA (ciclosporin); EVE (everolimus); R2\* (transverse relaxation rate) in s<sup>-1</sup>.

276 277



278 279

280

281

282

Figure 6. BOLD-derived transverse relaxation rate. Transverse relaxation rate R2\* according to medication group and time-point. CsA (ciclosporin); EVE (everolimus); R2\* (transverse relaxation rate).

#### 3.5. Resistive indices

Mean resistive indices as measured by duplex ultrasound scan are shown in Table 6. 283 Baseline RI values 4.5 months after transplantation corresponded to reference values in 284 kidney grafts [21]. At baseline, measured RI were by trend higher in the group random-285 ized to CsA than in the group randomized to EVE. At month 12 however, the difference 286 reached statistical significance due to a tendency to greater increase of RI over time in the 287 CsA-treated vs the EVE-treated group. No change was seen separately in the groups of 288 CsA- and EVE-treated patients over time (*p*=0.35 and *p*=0.80 respectively). 289

Table 6. Mean resistive indices measured by duplex ultrasound according to medication group and 290 time-point.

	CsA (n=6)	EVE (n=8)	<i>p</i> -value <sup>1</sup>
RI month 4.5	70.3±4.5	65.0±8.2	0.18
RI month 12	71.7±4.5	65.8±7.3	0.04
$\Delta RI$ (month 4.5-12)	1.4±3.7	$0.8 \pm 4.5$	0.76

<sup>1</sup> Mann-Whitney U-test. Values are expressed as mean ± standard deviation. CsA (ciclosporin); EVE 292 (everolimus); RI (resistive index). 293

#### 3.6. Ambulatory blood pressure measurement

Mean ABPM-derived blood pressure values are shown in Table 7. There was a trend 295 for increase in blood pressure from months 4.5 to 12 in the CsA-treated group whereas 296 blood pressure values in the EVE-treated groups showed no evident change even though 297 formal statistical analysis was not possible due to the number and distribution of cases at 298 month 12. Conversely, nocturnal blood pressure dipping showed an increasing trend in 299 the CsA-treated vs the EVE-treated group. 300

Table 7. Mean ABPM-derived blood pressure profile according to medication group and time-point. 301

	CsA (n=7) <sup>1</sup>	EVE (n=8)
Month 4.5		
BP sys	121.3±10.3	120.9±13.5
BP dia	77.1±7.6	79.9±12.8
BP mean	99.6±8.6	100.9±13.2
Dipping (sys/dia/mean)	1±6.9/5±9.1/2.7±7.3	7.3±12.1/9.5±12.9/8.9±12.9

291

#### J. Clin. Med. 2022, 11, x FOR PEER REVIEW

Month 12		
BP sys	121.0±1.0	122.1±8.1
BP dia	77.3±2.1	79.8±4.8
BP mean	99.7±1.5	101.1±6.2
Dipping (sys/dia/mean)	4.3±10.2/6.3±11.4/5.0±10.6	3.5±11.9/9.3±11/6.0±11.1
Change month 4.5-12		
$\Delta BP$ sys	9.7±7.4	1.25±13.5
$\Delta BP$ dia	6.3±6.8	-0.1±13.2
$\Delta BP$ mean	8±6.9	0.3±13.2
$\Delta$ Dipping (sys/dia/mean)	3.7±16.7/0.3±22.6/2.0±18.5	-3.8±10.0/-0.3±13.2/-2.9±10.9

<sup>1</sup>n=3 at month 12. Values are expressed as mean ± standard deviation. ABPM (ambulatory blood pressure monitoring); CsA (ciclosporin); EVE (everolimus); BP (blood pressure) in mmHg.

### 3.7. Laboratory parameters of graft function

Mean serum creatinine values and estimated glomerular filtration rates are shown 305 in Table 8. At baseline, there was a tendency for lower eGFR in the group randomized to 306 CsA. Whereas graft function was stable in the EVE-treated patients over time, it worsened 307 by trend in the CsA-treated group. However, values at twelve months as well as changes 308 from month 4.5 were not significantly different between medication groups. 309

Table 8. Mean serum creatinine values and estimated glomerular filtration rate according to medi-310 cation group and time-point. 311

	CsA (n=7)	EVE (n=8)	<i>p</i> -value <sup>1</sup>
Month 4.5			
Serum creatinine	112.0±21.0	12.01±40.0	0.46
eGFR	60.9±8.1	65.6±26.8	0.61
Month 12			
Serum creatinine	118.9±25.6	117±35.0	1.00
eGFR	57.1±11.0	65.5±19.7	0.40
Change month 4.5-12			
∆Serum creatinine	6.9±17.2	-4.4±22.3	0.46
$\Delta eGFR$	-3.7±10.3	-0.1±16.5	0.87

<sup>1</sup> Mann-Whitney U-test. Values are expressed as mean ± standard deviation. CsA (ciclosporin); EVE 312 (everolimus); eGFR (estimated glomerular filtration rate) according to chronic kidney disease epidemiology formula. Serum creatinine in µmol/l. 314

#### 3.8. Protocol biopsies

The number of available biopseies was six and five at baseline as well as five and five 316 at month 12 in the groups randomized to CsA and EVE respectively. No difference in the 317 degree of IFTA (reaching from none to mild) or arteriolar hyalinosis (reaching from none 318 to severe) was revealed between nor across medication groups (data not shown). 319

# 3.9. Correlation of fMRI parameters

To investigate medication-induced changes in fMRI parameters as well as correlations of fMRI parameters with selected clinical, biological and histological parameters, exploratory correlation testing was performed. 323

Changes in ADC<sub>D</sub> over time were not correlated with changes in eGFR or histological 324 parameters. Cortical ADC<sub>D</sub> at twelve months correlated negatively with the resistive in-325 dices measured by DUS ( $\tau$ =-0.511, *p*=0.040). 326

The perfusion fraction  $F_P$  correlated positively with eGFR at twelve months ( $\tau$ =0.629, p= 327 0.012). A negative correlation was found between F<sub>P</sub> and the diastolic and mean blood 328 pressure by ABPM ( $\tau$ =-0.584, p=0.020 and  $\tau$ =-0.523, p=0.038 respectively). 329 No correlation of R2\* with blood pressure, RI or graft function was noted. 330

11 of 15

313

315

302

303

304

321 322

12 of 15

# 4. Discussion

In this investigator-initiated study, we tested the hypothesis that diffusivity and per-332 fusion as well as tissue oxygenation as measured by fMRI techniques differ between kid-333 ney transplant recipients included in the ZEUS trial randomized to continuing ciclosporin 334 or to being switched to everolimus. The main findings are the following: (1) The mean 335 change in medullary and cortical ADC<sub>D</sub> significantly differed between both medication 336 groups showing increase in EVE-treated patients while decreasing in CsA-treated pa-337 tients. (2) Medullary ADC<sub>D</sub> significantly increased after switch to everolimus. (3) Medullary and cortical R2\* values showed inverse trends in medications groups with increasing values (i.e. reduced tissue oxygenation) in the CsA-treated group and decreasing values in the EVE-treated group. 341

First, ADCD as a marker of perfusion-free diffusion decreased in patients maintained on 343 CsA whereas it increased in patients converted to everolimus. The ADC<sub>D</sub> has previously 344 been shown to be reduced in various states of acute and chronic kidney diseases and to 345 correlate to biological kidney function markers and interstitial fibrosis [9, 18, 22-25]. This 346 course parallels the improvement of eGFR in EVE-treated patients reported in the ZEUS 347 trial, which was by trend also observed in our sub-study population. Further, the decrease 348 in diffusivity in CsA-treated patients might point to changes of tissue structure, possibly 349 due to chronic nephrotoxicity patterns of calcineurin inhibitors with development of 350 IFTA. Review of performed protocol biopsies did however not suggest increased propor-351 tion or severity of IFTA in the CsA-treated group even though the number of biopsies 352 available was low and a sampling error cannot be excluded. In addition, the reversibility 353 after 4.5 months of CsA treatment in the intervention group might suggest early injury or 354 alternative, potentially functional mechanisms. Furthermore, an influence of the higher 355 proportion of recipients of living donor kidneys in the EVE-treated group cannot be ex-356 cluded. 357

Second, R2\* values as marker of tissue oxygenation -if confounding factors are excluded-359 increased (lower tissue oxygenation) in CsA-maintained patients whereas it decreased 360 (higher tissue oxygenation) in EVE-treated patients. This may suggest ameliorated graft 361 tissue oxygenation under everolimus as compared to ciclosporin, possibly due to the ex-362 pected vasoconstrictor effect of calcineurin inhibitors [14]. However, hematocrit repre-363 sents a major confounding factor for BOLD-MRI with anemia leading to falsely-low R2\* 364 values and being expected as part of the everolimus side effect profile [26]. Despite lower 365 hemoglobin values in the core as well as the current study in EVE-treated patients, hemo-366 globin values were not significantly different between both medication groups at both 367 time-points [6]. 368

The DWI-derived fraction of perfusion F<sub>P</sub> showed no significant changes over time nor 370 between medication groups. Studies in kidney grafts have suggested lower FP values in 371 cases of decreased graft function and acute rejection as well as to correlate to chronic tu-372 bulo-interstitial damage [18, 24, 27]. In our study, the number of cases might have pre-373 vented a significant finding. FP correlated positively with eGFR at month 12, which corre-374 sponds to previous reports [18]. 375

In this study, no cortico-medullary differences were found for  $ADC_D$  and  $F_P$ . This is in 377 accordance with previous studies from our center showing a loss of cortico-medullary 378 differentiation over time in transplanted kidneys from living donors [18, 22, 23]. 379

Other relevant findings include significantly higher resistive indices as measured by DUS 381 in the CsA-treated group as compared to the EVE-treated group at month 12, possibly in 382 the context of calcineurin vasculopathy. However, this difference, albeit non-significant, 383 was present at baseline as well. In addition, higher resistive indices were associated with 384

331

338 339 340

342

358

369

376

J. Clin. Med. 2022, 11, x FOR PEER REVIEW

385

386

387 388

389

390

391

392

393

394 395

396

397 398

399

400

401

402

403

404

405

406

407

408

409

410

411 412

413

414

415

416

417

418

419

420

421

while remaining stable in the EVE-treated group. There are important limitations to our study: First, the number of subjects available for final analysis was limited precluding formal statistical analysis of the BOLD data as well as multivariate analysis of clinical correlations. Second, for technical reasons, three patients underwent MRI at 1.5T as opposed to 3T for the other patients. These data were therefore excluded for BOLD-MRI. Lastly, post hoc correction for multiple comparisons was not carried out in this exploratory analysis of clinical correlations. In conclusion, this prospective sub-study of the ZEUS trial suggests an impact of immunosuppressive regimen on fMRI parameters of the renal allograft. Author Contributions: Conceptualization, U.E. and L.M.; methodology, P.V. and U.E.; software, P.V.; validation, P.V., J.C. and L.M.; formal analysis, J.C., P.V. and L.M.; investigation, U.E., P.V.; resources, U.E. and P.V.; data curation, U.E. and P.V.; writing-original draft preparation, L.M.; writing-review and editing, J.C., P.V., U.E., B.V.; visualization, J.C. and L.M.; supervision, B.V.; project administration, U.E.; funding acquisition, U.E. and P.V. All authors have read and agreed to the published version of the manuscript. Funding: This research was funded by the SWISS NATIONAL SCIENCE FOUNDATION, grant number 320000-111959. Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Canton of Bern, Switzerland (protocol code 2004/213). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy reasons. Acknowledgments: We thank all patients who participated in this study. The results of this study have been presented at the 57th Congress of the European Renal Association-European Dialysis and Transplant Association. Conflicts of Interest: U.E. received honoraria from Astellas, Biotest, Chiesi and Novartis, not related to the presented data. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Wolfe, R. A.; Ashby, V. B.; Milford, E. L.; Ojo, A. O.; Ettenger, R. E.; Agodoa, L. Y.; Held, P. J.; Port, F. K., Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. The New England journal of medicine 1999, 341 (23), 1725-30. doi: 10.1056/NEJM199912023412303 Halloran, P. F., Immunosuppressive drugs for kidney transplantation. The New England journal of medicine 2004, 351 (26), 2715-29. 10.1056/NEJMra033540 Ekberg, H.; Tedesco-Silva, H.; Demirbas, A.; Vitko, S.; Nashan, B.; Gurkan, A.; Margreiter, R.; Hugo, C.; Grinyo, J. M.; Frei, U.; Vanrenterghem, Y.; Daloze, P.; Halloran, P. F.; Study, E. L.-S., Reduced exposure to calcineurin inhibitors in renal transplantation. The New England journal of medicine 2007, 357 (25), 2562-75. 10.1056/NEJMoa067411 Webster, A. C.; Lee, V. W.; Chapman, J. R.; Craig, J. C., Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. The Cochrane database of systematic reviews 2006, (2), CD004290. 10.1002/14651858.CD004290.pub2

lower cortical ADC<sub>D</sub> values at month 12. Similarly and expectedly, mean blood pressure

values as measured by ABPM increased by trend in the CsA-treated group over time

References

1.

2.

3.

4.

422

423 424

425

426

427

428

429

430

431

432

#### J. Clin. Med. 2022, 11, x FOR PEER REVIEW

5. Masson, P.; Henderson, L.; Chapman, J. R.; Craig, J. C.; Webster, A. C., Belatacept for kidney transplant recipients. The	434
Cochrane database of systematic reviews 2014, (11), CD010699. 10.1002/14651858.CD010699.pub2	435
6. Budde, K.; Becker, T.; Arns, W.; Sommerer, C.; Reinke, P.; Eisenberger, U.; Kramer, S.; Fischer, W.; Gschaidmeier,	436
H.; Pietruck, F.; Investigators, Z. S., Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney	437
transplants: an open-label, randomised, controlled trial. Lancet 2011, 377 (9768), 837-47. 10.1016/S0140-6736(10)62318-5	438
7. Budde, K.; Lehner, F.; Sommerer, C.; Reinke, P.; Arns, W.; Eisenberger, U.; Wuthrich, R. P.; Muhlfeld, A.; Heller,	439
K.; Porstner, M.; Veit, J.; Paulus, E. M.; Witzke, O.; Investigators, Z. S., Five-year outcomes in kidney transplant patients	440
converted from cyclosporine to everolimus: the randomized ZEUS study. American journal of transplantation : official journal of the	441
American Society of Transplantation and the American Society of Transplant Surgeons <b>2015</b> , 15 (1), 119-28. 10.1111/ajt.12952	442
8. Prasad, P. V., Functional MRI of the kidney: tools for translational studies of pathophysiology of renal disease. <i>American journal</i>	443
of physiology. Renal physiology <b>2006,</b> 290 (5), F958-74. doi: 10.1152/ajprenal.00114.2005	444
9. Mani, LY.; Vogt, B.; Vermathen, P., Functional Magnetic Resonance Imaging of the Kidney. In <i>Current Progress in Nephrology</i> ,	445
Ponticelli, C.; Visweswaran, R. K., Eds. TreeLife Media (A Div of Kothari Medical): Maharashtra India, 2022; pp 23-48.	446
10. Caroli, A.; Schneider, M.; Friedli, I.; Ljimani, A.; De Seigneux, S.; Boor, P.; Gullapudi, L.; Kazmi, I.;	447
Mendichovszky, I. A.; Notohamiprodjo, M.; Selby, N. M.; Thoeny, H. C.; Grenier, N.; Vallee, J. P., Diffusion-weighted	448
magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper. Nephrology, dialysis,	449
transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018, 33 (suppl_2),	450
ii29-ii40. 10.1093/ndt/gfy163	451
11. Pruijm, M.; Mendichovszky, I. A.; Liss, P.; Van der Niepen, P.; Textor, S. C.; Lerman, L. O.; Krediet, C. T. P.; Caroli,	452
A.; Burnier, M.; Prasad, P. V., Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue	453
oxygenation: a statement paper and systematic review. Nephrology, dialysis, transplantation : official publication of the European Dialysis	454
and Transplant Association - European Renal Association 2018, 33 (suppl_2), ii22-ii28. 10.1093/ndt/gfy243	455
12. Mani, LY.; Seif, M.; Nikles, F.; Tshering Vogel, D. W.; Diserens, G.; Martirosian, P.; Burnier, M.; Vogt, B.;	456
Vermathen, P., Hip Position Acutely Affects Oxygenation and Perfusion of Kidney Grafts as Measured by Functional Magnetic	457
Resonance Imaging Methods-The Bent Knee Study. Frontiers in medicine 2021, 8, 697055. 10.3389/fmed.2021.697055	458
13. Hofmann, L.; Simon-Zoula, S.; Nowak, A.; Giger, A.; Vock, P.; Boesch, C.; Frey, F. J.; Vogt, B., BOLD-MRI for the	459
assessment of renal oxygenation in humans: acute effect of nephrotoxic xenobiotics. Kidney international 2006, 70 (1), 144-50.	460
10.1038/sj.ki.5000418	461
14. Naesens, M.; Kuypers, D. R.; Sarwal, M., Calcineurin inhibitor nephrotoxicity. Clinical journal of the American Society of	462
Nephrology : CJASN <b>2009,</b> 4 (2), 481-508. 10.2215/CJN.04800908	463
15. World Medical Association, World Medical Association Declaration of Helsinki: ethical principles for medical research	464
involving human subjects. JAMA : the journal of the American Medical Association 2013, 310 (20), 2191-4. doi: 10.1001/jama.2013.281053	465
16. Steering Committee of the Istanbul Summit, Organ trafficking and transplant tourism and commercialism: the Declaration of	466
Istanbul. <i>Lancet</i> <b>2008</b> , 372 (9632), 5-6. doi: 10.1016/S0140-6736(08)60967-8	467
17. Seif, M.; Mani, L. Y.; Lu, H.; Boesch, C.; Reyes, M.; Vogt, B.; Vermathen, P., Diffusion tensor imaging of the human	468
kidney: Does image registration permit scanning without respiratory triggering? Journal of magnetic resonance imaging : JMRI 2016, 44	469
(2), 327-34. 10.1002/jmri.25176	470
18. Eisenberger, U.; Thoeny, H. C.; Binser, T.; Gugger, M.; Frey, F. J.; Boesch, C.; Vermathen, P., Evaluation of renal	471
allograft function early after transplantation with diffusion-weighted MR imaging. European radiology 2010, 20 (6), 1374-83.	472
10.1007/s00330-009-1679-9	473

#### J. Clin. Med. 2022, 11, x FOR PEER REVIEW

19. Vermathen, P.; Binser, T.; Boesch, C.; Eisenberger, U.; Thoeny, H. C., Three-year follow-up of human transplanted	474
kidneys by diffusion-weighted MRI and blood oxygenation level-dependent imaging. Journal of magnetic resonance imaging : JMRI	475
<b>2012,</b> 35 (5), 1133-8. 10.1002/jmri.23537	476
20. Seif, M.; Eisenberger, U.; Binser, T.; Thoeny, H. C.; Krauer, F.; Rusch, A.; Boesch, C.; Vogt, B.; Vermathen, P., Renal	477
Blood Oxygenation Level-dependent Imaging in Longitudinal Follow-up of Donated and Remaining Kidneys. Radiology 2016, 279	478
(3), 795-804. 10.1148/radiol.2015150370	479
21. Jakobsen, J. A.; Brabrand, K.; Egge, T. S.; Hartmann, A., Doppler examination of the allografted kidney. Acta radiologica	480
(Stockholm, Sweden : 1987) <b>2003</b> , 44 (1), 3-12.	481
22. Thoeny, H. C.; Zumstein, D.; Simon-Zoula, S.; Eisenberger, U.; De Keyzer, F.; Hofmann, L.; Vock, P.; Boesch, C.;	482
Frey, F. J.; Vermathen, P., Functional evaluation of transplanted kidneys with diffusion-weighted and BOLD MR imaging: initial	483
experience. Radiology 2006, 241 (3), 812-21. doi: 10.1148/radiol.2413060103	484
23. Eisenberger, U.; Binser, T.; Thoeny, H. C.; Boesch, C.; Frey, F. J.; Vermathen, P., Living renal allograft transplantation:	485
diffusion-weighted MR imaging in longitudinal follow-up of the donated and the remaining kidney. Radiology 2014, 270 (3), 800-8.	486
10.1148/radiol.13122588	487
24. Sulkowska, K.; Palczewski, P.; Wojcik, D.; Ciszek, M.; Sanko-Resmer, J.; Wojtowicz, J.; Leszkiewicz, M.; Golebiowski,	488
M., Intravoxel incoherent motion imaging in monitoring the function of kidney allograft. Acta radiologica (Stockholm, Sweden : 1987)	489
<b>2019,</b> 60 (7), 925-932. 10.1177/0284185118802598	490
25. Hueper, K.; Khalifa, A. A.; Bräsen, J. H.; Vo Chieu, V. D.; Gutberlet, M.; Wintterle, S.; Lehner, F.; Richter, N.;	491
Peperhove, M.; Tewes, S.; Weber, K.; Haller, H.; Wacker, F.; Gwinner, W.; Gueler, F.; Hartung, D., Diffusion-Weighted	492
imaging and diffusion tensor imaging detect delayed graft function and correlate with allograft fibrosis in patients early after kidney	493
transplantation. Journal of magnetic resonance imaging : JMRI 2016, 44 (1), 112-21. 10.1002/jmri.25158	494
26. Niendorf, T.; Pohlmann, A.; Arakelyan, K.; Flemming, B.; Cantow, K.; Hentschel, J.; Grosenick, D.; Ladwig, M.;	495
Reimann, H.; Klix, S.; Waiczies, S.; Seeliger, E., How bold is blood oxygenation level-dependent (BOLD) magnetic resonance	496
imaging of the kidney? Opportunities, challenges and future directions. Acta physiologica 2015, 213 (1), 19-38. 10.1111/apha.12393	497
27. Poynton, C. B.; Lee, M. M.; Li, Y.; Laszik, Z.; Worters, P. W.; Mackenzie, J. D.; Courtier, J., Intravoxel incoherent motion	498
analysis of renal allograft diffusion with clinical and histopathological correlation in pediatric kidney transplant patients: A	499
preliminary cross-sectional observational study. Pediatric Transplantation 2017, 21 (6), e12996. https://doi.org/10.1111/petr.12996	500
	501